CBD Oil for Sleep and Diabetes: How CBD Addresses Glycemic Disruption, Diabetic Neuropathy Pain, and Autonomic Sleep Dysregulation

Diabetes, Medications, and CBD: Essential Safety Context

Diabetes management requires careful coordination with your prescribing physician before adding any supplement including CBD. The most critical interaction: CBD combined with insulin or sulfonylureas (glipizide, glimepiride, glyburide) carries an additive hypoglycemia risk — both lower blood glucose through different mechanisms, and the combination may produce symptomatic hypoglycemia particularly during the fasting state of sleep. All people with diabetes using insulin or sulfonylureas must disclose CBD use to their physician before initiating. Blood glucose monitoring frequency may need to increase during CBD initiation. If you use a continuous glucose monitor (CGM), this provides an excellent safety tool for monitoring CBD's glycemic effect during the titration period. This guide covers CBD's mechanisms relevant to diabetes sleep disruption and is for informational purposes only — it does not replace diabetes management under physician supervision.

Type 1 Diabetes: Hypoglycemia Unawareness and Neuropathy Priority

Type 1 diabetes (autoimmune beta-cell destruction, absolute insulin dependence) produces sleep disruption predominantly through nocturnal hypoglycemia — the most frequent and acutely dangerous sleep disruption mechanism in T1DM. Hypoglycemia unawareness (impaired sympathoadrenal counter-regulatory response to hypoglycemia, more common in long-duration T1DM) reduces the arousal signal from nocturnal hypoglycemic episodes, increasing severe hypoglycemia risk. CGM use is highly recommended for T1DM patients considering CBD, because CBD's potential additive glucose-lowering effect (PPARγ/CB1 mechanisms) requires monitoring during initiation. The DPN mechanism is relevant for long-duration T1DM (10+ years) where peripheral neuropathy prevalence approaches that of T2DM. For T1DM sleep, the TRPV1/CB1 DPN pain mechanism and HPA normalization for hypoglycemia counter-regulatory surge attenuation are the most relevant mechanisms; the insulin-sensitizing PPARγ mechanism is less central (insulin is exogenous in T1DM; sensitivity varies). T1DM patients must have endocrinologist clearance before initiating CBD given the hypoglycemia risk, CGM or frequent monitoring during initiation, and awareness that CBD may affect insulin requirements.

Type 2 Diabetes: Insulin Resistance, Neuropathy, and the Bidirectional Sleep-Glycemia Loop

Type 2 diabetes (insulin resistance + relative insulin deficiency, often obesity-associated) produces the broadest sleep disruption profile: the bidirectional sleep-insulin resistance cycle (N3 deprivation worsens insulin resistance, which worsens glycemic control, which worsens sleep); DPN from chronic hyperglycemia; OSA comorbidity from obesity; autonomic neuropathy in longer-duration T2DM; and hyperglycemia-driven nocturia. For T2DM sleep, PPARγ insulin sensitization is the most metabolically distinct mechanism — addressing insulin resistance directly, which is the primary T2DM pathophysiology. The CB2 anti-inflammatory mechanism is also particularly relevant for T2DM: the chronic low-grade systemic inflammation of metabolic syndrome/T2DM (elevated TNF-α, IL-6, IL-1β from adipose tissue macrophage activation) suppresses N3 through the same cytokine-driven sleep architecture disruption mechanisms as autoimmune disease, but at lower severity and with the mechanistic difference that the inflammation originates from adipose tissue rather than systemic autoimmunity. T2DM patients on oral medications (metformin, GLP-1 agonists, SGLT2 inhibitors, DPP-4 inhibitors, sulfonylureas) need physician disclosure for CYP interaction assessment, with sulfonylureas requiring the most careful monitoring.

Diabetes Medication Interactions — Physician Disclosure Required Before Initiating CBD

Insulin (ALL formulations — basal, rapid, mixed) — MOST CRITICAL INTERACTION: CBD's potential glucose-lowering effects (PPARγ insulin sensitization, CB1 glycemic modulation) combined with exogenous insulin creates an additive hypoglycemia risk that is the most serious pharmacodynamic interaction in the diabetes-CBD context. Both agents lower blood glucose through different mechanisms, and the combination during the fasting state of sleep — when hepatic glycogen stores are limited and glucose demand is maintained for CNS function — may produce symptomatic or severe nocturnal hypoglycemia. This risk is not merely theoretical: the overnight fast combined with CBD-enhanced insulin sensitivity means glucose can drop more rapidly than daytime use patterns suggest. Mandatory steps: endocrinologist or prescribing physician disclosure; frequent CGM or blood glucose monitoring during CBD initiation; conservative dose titration starting at 5–10 mg and increasing very gradually; monitoring for nighttime hypoglycemia symptoms; and awareness that insulin dose adjustment may be necessary as CBD's metabolic effects accumulate over weeks.

Sulfonylureas (glipizide, glimepiride, glyburide, glibenclamide) — HIGH PRIORITY: Sulfonylureas stimulate pancreatic insulin secretion regardless of blood glucose level — a mechanism that produces hypoglycemia risk as their primary side effect even without CBD. CBD adds both CYP2C9 inhibition (sulfonylureas are primarily CYP2C9 substrates — CBD may elevate plasma sulfonylurea levels) and pharmacodynamic additive glucose-lowering. The combined risk of elevated sulfonylurea plasma levels plus CBD's glucose-lowering mechanism is the most pharmacokinetically significant diabetes drug interaction beyond insulin. Physician disclosure mandatory; blood glucose monitoring essential during initiation; consider whether sulfonylurea dose adjustment is appropriate as CBD's effects establish over 4–6 weeks.

Metformin: Metformin's primary mechanism (AMPK activation → hepatic gluconeogenesis suppression, improved insulin sensitivity) has low CYP interaction — metformin is not metabolized by CYP enzymes (it is renally excreted unchanged). CBD's PPARγ mechanism and metformin's AMPK mechanism are complementary insulin-sensitizing approaches via different pathways, suggesting potential additive glycemic benefit without the acute hypoglycemia risk of insulin/sulfonylureas (neither metformin nor CBD reliably causes hypoglycemia when used without insulin secretagogues). Physician disclosure still warranted, but the metformin-CBD combination is generally lower pharmacodynamic risk than insulin or sulfonylurea combinations.

GLP-1 receptor agonists (semaglutide/Ozempic/Wegovy, liraglutide, dulaglutide, exenatide): GLP-1 agonists are glucose-dependent insulin secretagogues (they enhance insulin secretion only when blood glucose is elevated) — this glucose-dependence reduces hypoglycemia risk compared to insulin and sulfonylureas. GLP-1 agonists are not CYP-metabolized (protein catabolism). The pharmacodynamic combination with CBD — both agents affecting insulin sensitivity, appetite, and gastrointestinal motility — may produce complementary or additive GI effects (nausea, which is already a common GLP-1 side effect) and complementary glycemic benefit. CBD's gastroparesis CB1 motility effect may interact with GLP-1 agonists' own GI motility effects. Physician disclosure warranted; monitor GI tolerability during co-initiation.

SGLT2 inhibitors (empagliflozin/Jardiance, dapagliflozin/Farxiga, canagliflozin): SGLT2 inhibitors lower blood glucose by increasing renal glucose excretion — a mechanism that reduces osmotic diuresis at therapeutic blood glucose levels (by eliminating excess glucose renally rather than allowing osmotic diuresis from hyperglycemia) but may shift fluid balance. SGLT2 inhibitors are not significant CYP substrates; CYP interaction risk with CBD is low. The SGLT2 inhibitor mechanism (reducing hyperglycemia) and CBD's PPARγ mechanism are complementary glycemic approaches. One pharmacodynamic consideration: SGLT2 inhibitors cause glucosuria that may modestly increase hypoglycemia risk when combined with agents that also lower blood glucose (including CBD), though SGLT2 inhibitors alone rarely cause hypoglycemia. Physician disclosure warranted; lower interaction priority than insulin or sulfonylureas.

Pregabalin and gabapentin (prescribed for DPN pain): Pregabalin (Lyrica) and gabapentin (Neurontin) are first-line pharmacological treatments for DPN neuropathic pain — they work by reducing calcium channel activity in sensitized dorsal horn neurons, blunting the central sensitization that amplifies DPN pain. Both are renally excreted, not CYP-metabolized. The pharmacodynamic combination with CBD is additive sedation (both CBD and gabapentinoids are CNS depressants) with potential complementary neuropathic pain relief — TRPV1/CB1 peripheral mechanism (CBD) plus calcium channel central sensitization reduction (gabapentinoid). Physician disclosure warranted; morning grogginess or excessive sedation may indicate dose adjustment is needed in either agent. The combination may allow lower pregabalin/gabapentin doses (relevant because dose-dependent side effects of dizziness, sedation, and weight gain limit gabapentinoid use).

Tricyclic antidepressants (amitriptyline, nortriptyline — prescribed for DPN): Low-dose tricyclics are commonly prescribed for DPN pain through their sodium channel blockade and norepinephrine reuptake inhibition (which activates descending inhibitory pathways). They are CYP2D6 substrates; CBD's CYP2D6 inhibition may elevate tricyclic plasma levels. Combined with CBD's additive sodium channel-relevant TRPV1/CB1 mechanisms, the combination may provide complementary DPN pain relief at lower tricyclic doses. Physician disclosure and dose monitoring warranted given CYP interaction and combined CNS depressant effect on sleep.

Diabetes Sleep Dosing Protocol: Glycemic Monitoring During Titration

Critical pre-initiation step for insulin and sulfonylurea users: Confirm physician clearance and establish a blood glucose monitoring plan before taking any CBD. If you use a CGM, document your overnight glucose pattern for 7 days before CBD initiation to establish a baseline — this lets you detect any CBD-attributable glycemic changes against your normal pattern during titration. If you do not use a CGM, increase fingerstick monitoring frequency during the first 2–4 weeks of CBD initiation, particularly a pre-bedtime and 2–3 AM check to capture nocturnal effects.

Standard titration (metformin, GLP-1, SGLT2, DPP-4 — lower hypoglycemia risk): Begin at 15–20 mg nanoemulsion CBD in the evening, 30–45 minutes before intended sleep. Increase by 5–10 mg every 1–2 weeks, targeting 35–50 mg as the primary therapeutic range. The TRPV1 DPN pain desensitization mechanism will begin producing sleep benefit in this group at 6–8 weeks; the PPARγ metabolic mechanism accumulates over 8–12 weeks. Track DPN pain rating at bedtime (0–10), number of nocturnal awakenings, and nocturia frequency separately — these are distinct mechanisms and may improve on different timelines.

Conservative titration (insulin, sulfonylurea users): Begin at 10 mg nanoemulsion CBD in the evening with food (food slows absorption and modestly blunts peak plasma levels), after physician clearance. Increase by 5 mg every 2 weeks maximum, monitoring overnight glucose pattern at each increment before increasing further. Target range 25–35 mg (lower than standard to reflect hypoglycemia caution). If nighttime hypoglycemia events increase in frequency or severity during CBD initiation, pause titration and discuss insulin/sulfonylurea dose adjustment with your physician — do not simply discontinue CBD without physician guidance, as abrupt withdrawal of either agent can destabilize glycemic control.

Timeline and tracking: DPN pain improvement: 6–8 weeks (TRPV1 desensitization timeline). Nocturia reduction: may begin 8–12 weeks if glycemic control improves via PPARγ mechanism. Sleep architecture improvement: 4–8 weeks (HPA/adenosine mechanisms; earlier than DPN or glycemic mechanisms). Total minimum evaluation: 12 weeks, tracking DPN pain, nocturnal awakenings, nocturia episodes, and morning energy separately. A continuous glucose monitor provides the most complete picture of CBD's metabolic effects during the evaluation period — overnight glucose curves during the 8–12 week window will show whether glycemic control is improving as part of the multi-mechanism response.

Does CBD oil help with diabetic neuropathy pain at night?

CBD oil addresses diabetic peripheral neuropathy (DPN) pain through two complementary mechanisms that are particularly relevant to the nocturnal neuropathic pain that disrupts diabetic sleep. TRPV1 desensitization targets the sensitized TRPV1 channels in small C-fiber and Aδ-fiber nociceptors that underlie DPN's burning and dysesthetic pain — CBD's initial TRPV1 activation followed by calcium-mediated desensitization reduces the spontaneous nociceptor firing that peaks at night when competing sensory stimuli are reduced. CB1 descending inhibitory pathway activation addresses the central sensitization component: CBD activates the periaqueductal gray and rostral ventromedial medulla CB1 receptors that drive spinal pain inhibition — reducing dorsal horn amplification of peripheral DPN signals. The TRPV1 desensitization timeline (6–8 weeks of consistent daily dosing) is the primary mechanism for DPN, with meaningful nocturnal pain reduction typically beginning in this window. The topical cream applied to feet and lower legs at bedtime provides an additional localized TRPV1/CB1 mechanism specifically at the DPN anatomical site with no systemic absorption — useful as an adjunct to oral dosing or as a starting point for insulin users with hypoglycemia concerns during oral titration.

Is CBD oil safe for people with diabetes who take insulin?

CBD oil can be used by people with insulin-dependent diabetes, but it requires physician clearance, glycemic monitoring during titration, and a conservative initiation protocol due to the additive hypoglycemia risk. CBD's PPARγ insulin-sensitizing and CB1 hepatic glucose-regulatory mechanisms may lower blood glucose — combined with exogenous insulin, which also lowers blood glucose, the combination can produce hypoglycemia, particularly during the overnight fasting period. The steps for safe initiation: (1) discuss CBD with your endocrinologist or prescribing physician before starting; (2) if using a CGM, document your baseline overnight glucose pattern for 7 days pre-initiation; (3) begin at the lowest feasible dose (10 mg) with a small evening snack; (4) monitor overnight glucose during the first week at each dose; (5) increase dose only after physician review of monitoring data. The topical muscle and joint cream is an option for DPN pain with essentially zero systemic absorption — no glycemic interaction — allowing localized neuropathic pain relief while the oral titration is being carefully managed. Many people with insulin-treated diabetes use CBD successfully for DPN sleep disruption; the key is careful initiation under physician supervision rather than avoidance.

Can CBD oil help with nocturia from diabetes affecting sleep?

Diabetic nocturia — nighttime urination driven by osmotic diuresis from hyperglycemia — is addressed by CBD oil's glycemic mechanism rather than any direct urological mechanism. CBD's PPARγ activation improves insulin sensitivity and promotes adiponectin secretion, which enhances peripheral glucose uptake and reduces fasting blood glucose; CB1 hepatic regulation modulates gluconeogenesis, the primary source of fasting and dawn-phenomenon hyperglycemia. As glycemic control improves through these mechanisms over 8–12 weeks, the osmotic diuretic pressure (glucose spilling into urine only when blood glucose exceeds approximately 180 mg/dL) is reduced, which directly reduces the nocturia frequency driven by hyperglycemia-induced glucosuria. Honest expectation: this glycemic mechanism for nocturia reduction requires meaningful improvement in HbA1c and fasting blood glucose to produce clinically significant nocturia reduction — CBD's insulin-sensitizing effect is adjunctive to (not a replacement for) primary diabetes medications and lifestyle management. For people with well-controlled blood glucose whose nocturia has a different etiology (benign prostatic hyperplasia, bladder dysfunction, excess evening fluid intake), CBD's glycemic mechanism will not address the nocturia source, and appropriate specialist evaluation is warranted.

Does CBD oil affect blood sugar or insulin resistance?

CBD oil has documented preclinical effects on insulin sensitivity and blood glucose through two primary mechanisms. PPARγ activation — CBD acts as a PPARγ agonist, the same nuclear receptor targeted by thiazolidinedione medications (pioglitazone, rosiglitazone) — promotes adiponectin secretion from adipose tissue, which improves peripheral insulin sensitivity, reduces hepatic gluconeogenesis, and enhances skeletal muscle glucose uptake. CB1 receptor modulation in hepatic tissue affects gluconeogenesis regulation, the primary source of fasting blood glucose. These mechanisms suggest CBD may modestly improve insulin sensitivity and glycemic control — a beneficial metabolic effect for Type 2 diabetes that contributes to sleep improvement through reduced hyperglycemia-driven nocturia and inflammatory sleep disruption. In human clinical research, CBD's direct glycemic effects have not been established in rigorous trials; the preclinical evidence is strongest in rodent diabetes models. CBD should not be used as a primary blood glucose management strategy or as a substitute for prescribed diabetes medications. The glycemic effects of CBD are an adjunctive benefit in the context of comprehensive diabetes management — including medications, diet, and physical activity as directed by your physician.

Can CBD oil help with the sleep deprivation-insulin resistance cycle?

The bidirectional relationship between sleep deprivation and insulin resistance — where poor sleep worsens glycemic control and poor glycemic control worsens sleep — is one of the most clinically relevant aspects of diabetes sleep management that standard diabetes care often fails to address explicitly. CBD oil engages both sides of this bidirectional cycle. On the sleep side: CBD's adenosine A1 activation deepens N3 slow-wave sleep architecture, which is the specific sleep stage whose deprivation (not just total sleep duration) reduces insulin sensitivity by approximately 25% within 3–4 nights. By improving N3 quality, CBD's sleep architecture mechanism directly targets the mechanism by which sleep deprivation causes insulin resistance. On the glycemic side: CBD's PPARγ insulin-sensitizing mechanism addresses insulin resistance directly, and its HPA normalization mechanism reduces cortisol — the hormone directly antagonizing insulin's action that is elevated by both sleep deprivation and nocturnal hypoglycemia. Breaking this reinforcing cycle requires simultaneous intervention on both sides; CBD's mechanisms engage both the sleep architecture and the insulin sensitivity dimensions of the cycle in a coordinated multi-mechanism approach.

Does CBD oil help with autonomic neuropathy affecting sleep?

Diabetic autonomic neuropathy disrupts sleep through cardiac autonomic neuropathy (reduced nocturnal HRV, impaired parasympathetic shift during N3, and sometimes non-dipping nocturnal blood pressure) and gastroparesis (nocturnal GI discomfort from delayed gastric emptying compounded by the supine sleep position). CBD's ANS parasympathetic-promoting mechanism — 5-HT1A-mediated locus coeruleus suppression reducing noradrenergic sympathetic drive; CB1 hypothalamic ANS regulation promoting parasympathetic shift — directly addresses the sympathetic dominance and reduced vagal tone of cardiac autonomic neuropathy. Multiple human studies have documented CBD's HRV-improving effect, which reflects increased parasympathetic tone — relevant for CAN's nocturnal HRV deficit. For gastroparesis: CBD's enteric CB1 mechanism (the ECS is densely expressed in enteric neurons and modulates gastrointestinal motility) may provide modest gastroparesis symptom relief; preclinical evidence supports cannabinoid effects on gastric emptying, though clinical evidence is limited. Cardiac autonomic neuropathy requires physician management — CBD's vagal-promoting mechanism is an adjunct to CAN management (including optimizing glycemic control, treating underlying diabetes, and managing cardiovascular risk) rather than a substitute for it. HRV monitoring with a consumer wearable over 8–12 weeks of CBD provides an objective indicator of autonomic benefit.

Does CBD oil interact with metformin?

CBD oil has a low pharmacokinetic interaction risk with metformin — metformin is not metabolized by CYP enzymes (it is excreted renally unchanged), so CBD's CYP inhibition does not elevate metformin plasma levels. The two agents have complementary but mechanistically distinct insulin-sensitizing actions: metformin activates AMPK → reduces hepatic gluconeogenesis, and CBD activates PPARγ → promotes adiponectin-mediated peripheral insulin sensitivity. This complementary mechanism profile suggests additive glycemic benefit without the acute hypoglycemia risk of insulin or sulfonylurea combinations, because neither metformin nor CBD alone reliably causes hypoglycemia through insulin-secretion-dependent mechanisms (hypoglycemia from metformin alone is rare; CBD's glucose-lowering is modest). For metformin users, the initiation protocol is less restrictive than for insulin/sulfonylurea users: the standard 15–20 mg starting dose with gradual titration is appropriate, with standard monitoring rather than intensive CGM requirements. Physician disclosure is still recommended as routine medical transparency, and any unexplained GI symptoms during CBD initiation (gastrointestinal effects are common to both metformin and CBD at higher doses) should be reported.

Can CBD oil be used with pregabalin for diabetic neuropathy pain?

CBD oil and pregabalin (Lyrica) address diabetic peripheral neuropathy pain through complementary mechanisms — pregabalin reduces central sensitization through voltage-gated calcium channel modulation in the dorsal horn, while CBD addresses peripheral nociceptor sensitization through TRPV1 desensitization and activates descending inhibitory pathways through CB1. The mechanisms are non-overlapping and potentially additive for DPN pain relief. The primary consideration for the combination: additive CNS depressant sedation — both pregabalin and CBD have sedating effects that are additive, particularly at night. This sedation can be therapeutically valuable for DPN sleep disruption (deeper sleep, reduced DPN pain awakening) but may cause excessive morning grogginess, balance impairment, or cognitive blunting if the combined doses are high. Physician disclosure is warranted; the combination may allow lower pregabalin doses (reducing pregabalin's dose-dependent side effects of weight gain, dizziness, and cognitive effects) while maintaining combined DPN pain management through CBD's complementary mechanisms. Pharmacokinetically, pregabalin is not a significant CYP substrate — CYP interaction risk with CBD is low. Begin CBD at lower doses when combining with pregabalin and monitor for excessive sedation.

How long does CBD oil take to work for diabetic sleep problems?

CBD oil's timeline for diabetes-related sleep improvement varies by mechanism, and tracking the different components separately provides the most informative picture. General sleep architecture improvement (easier sleep onset, fewer early awakenings unrelated to DPN pain or nocturia) from HPA normalization and ANS parasympathetic mechanisms typically begins at 4–6 weeks of consistent evening dosing — the earliest response in the diabetes sleep profile. Diabetic peripheral neuropathy pain reduction — the TRPV1 desensitization mechanism — typically begins showing nocturnal pain score improvement at 6–8 weeks. Glycemic effects from PPARγ and CB1 metabolic mechanisms — which would reduce nocturia frequency and inflammatory sleep suppression — accumulate over 8–12 weeks and require meaningful improvement in glycemic markers (HbA1c, fasting glucose) to translate into nocturia reduction. The minimum evaluation period for diabetes is 12 weeks, tracking DPN pain score, nocturia episodes, number of nocturnal awakenings, and morning energy separately. People using a CGM can also track overnight glucose patterns as an objective metabolic indicator of CBD's glycemic mechanism, which provides a more precise picture of the metabolic benefit than HbA1c alone during the first 12 weeks.

What is the best CBD oil product for diabetic neuropathy sleep pain?

For diabetic peripheral neuropathy sleep disruption specifically, the optimal CBD oil approach combines systemic and topical delivery. The Nano CBD Broad Spectrum Oil (sublingual nanoemulsion, 15–20 mg starting dose, 30 minutes before sleep) provides systemic TRPV1 desensitization and CB1 descending inhibitory pathway activation for the central sensitization component of DPN — and its precise dose control is essential for the conservative titration required for insulin and sulfonylurea users. The Nano CBD Infused Muscle and Joint Cream applied to feet and lower legs 30–45 minutes before sleep provides localized TRPV1/CB1 peripheral nociceptor suppression at the DPN anatomical site (bilateral distal lower extremities) with zero systemic absorption — no glycemic interaction risk, making it the safest starting point for insulin-treated patients who need DPN pain relief immediately while building confidence in systemic dosing gradually. After the sublingual oil is established and tolerated, adding the Nano CBD Water-Soluble Broad Spectrum Softgel at bedtime extends overnight DPN pain coverage through the vulnerable early-morning hours (3–6 AM) when sublingual levels wane and DPN pain often peaks. The topical cream plus sublingual oil combination addresses DPN through peripheral (topical) and central (oral/systemic) mechanisms simultaneously — a dual-route approach matched to DPN's dual pain pathology of peripheral nociceptor sensitization and central amplification.

Medical Disclaimer

This article is for informational and educational purposes only. It is not intended to diagnose, treat, cure, or prevent diabetes, diabetic peripheral neuropathy, diabetic autonomic neuropathy, obstructive sleep apnea, or any other health condition. CBD oil is not a diabetes medication and does not replace insulin, oral diabetes medications, or physician-supervised diabetes management. The statements in this article have not been evaluated by the Food and Drug Administration. People with diabetes using insulin or sulfonylureas (glipizide, glimepiride, glyburide) must disclose CBD use to their physician before initiating due to additive hypoglycemia risk; blood glucose monitoring is required during CBD titration. CBD's effects on blood glucose, insulin resistance, and HbA1c have not been established in rigorous human clinical trials; preclinical evidence is the primary basis for the metabolic mechanism discussion in this article. CBD may interact with multiple diabetes medications through CYP pharmacokinetic pathways; complete medication disclosure to your prescribing physician is required before initiating CBD. The topical cream discussed in this article is for DPN pain symptom relief and does not treat diabetic neuropathy progression. Individual responses to CBD vary significantly. Always work with your diabetes care team before making any changes to your diabetes management regimen, including adding supplements such as CBD.